• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA approves Canadian company's topical acne gel

Article

The U.S. Food and Drug Administration (FDA) has approved a topical acne gel developed and manufactured by Canadian drug company QLT Inc.

The U.S. Food and Drug Administration (FDA) has approved a topical acne gel developed and manufactured by Canadian drug company QLT Inc.

The Vancouver, British Columbia-based company, says its Aczone gel is the only topical acne treatment containing dapsone, a drug that is taken in pill form to treat certain skin rashes and leprosy. QLT says potential patients will need to be screened for a certain type of anemia before starting the therapy.

Shares of QLT jumped 50 cents, or 4.8 percent, to $11.02 in after-hours trading following the news that Aczone had been granted FDA approval.

Related Videos
Video 2 - "Atopic Dermatitis and Contact Dermatitis: Navigating Intersecting Pathways and Optimal Management Strategies"
Video 1 - "Decoding Atypical Atopic Dermatitis: Unraveling Complex Cases and Advanced Diagnostic Strategies"
Elizabeth Kiracofe, MD, an expert on atopic dermatitis
© 2024 MJH Life Sciences

All rights reserved.